Curaleaf Holdings

Curaleaf Holdings earns a Neutral rating at a 55.6 composite score, with conviction at 2/5. Fundamentals contribute the strongest pillar at 76.0, supported by a 95.9 market-cap tier subscore, an 82.0 gross-margin subscore, a 77.1 operating-margin subscore, and a 90.0 cash-runway subscore reflecting positive EBITDA alongside a continuing net loss. Regulatory contributes 58.0, anchored by 80.0 scores for jurisdiction posture and enforcement, but restrained by a 25.0 filing-cadence score. Market contributes only 40.0 because no quote was available through institutional pricing feeds. Editorial contributes 30.0, consistent with no newsroom or brief activity in CIN newsroom coverage. The weaker market and editorial pillars prevent the solid fundamentals profile from producing an Overweight rating.

Licensed fundamentals data show year-over-year revenue growth of 5.7%, a gross margin of roughly 49.2%, and an operating margin of just 0.23%. The gross-margin level demonstrates substantial product-level profitability, while the thin operating margin shows that little of that profitability currently reaches operating earnings. EBITDA stands near $212.5 million, but net income remains negative by approximately $100.2 million. That combination supports the elevated cash-runway subscore without changing the stated stretched financial condition; positive EBITDA does not erase the bottom-line loss. Market capitalization is approximately $2.50 billion, reinforcing the high size-tier contribution. Primary regulatory filings show the latest filing dated July 8, 2026. Thirteen regulatory events occurred across the prior 180 days, yet none appeared in the latest 90-day period, producing the weak cadence assessment. Zero enforcement hits support the stronger enforcement subscore.

The clearest forward catalyst sits within fundamentals, the dominant pillar. Curaleaf already carries a strong gross-margin score and positive EBITDA, so greater conversion of gross profit into operating income delivers the most direct path toward a higher composite. Revenue growth provides a positive base, but the current operating spread and net loss keep conviction limited and preserve the Neutral band. Regulatory posture remains supportive, while sparse recent filings, unavailable market pricing, and absent editorial activity offer no offsetting catalyst. The single most important signal to watch is sustained expansion in operating margin accompanied by a narrowing net loss in the next primary regulatory filings.